<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03564158</url>
  </required_header>
  <id_info>
    <org_study_id>Rempex 512</org_study_id>
    <nct_id>NCT03564158</nct_id>
  </id_info>
  <brief_title>Evaluate Effects of Meropenem-Vaborbactam on QT/QTc in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Placebo- and Positive-Controlled, Crossover Study to Evaluate the Effect of Meropenem-Vaborbactam on the QT/QTc Interval in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biomedical Advanced Research and Development Authority</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Melinta Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Thorough-QT (TQT) study in healthy volunteers will be conducted in two phases. Phase One&#xD;
      will be used to identify a safe supratherapeutic dose to be used in the TQT study (Phase&#xD;
      Two). Phase Two will be a 4-way crossover TQT study. Thirty-two subjects will receive all 4&#xD;
      of the following treatments in randomized sequence.&#xD;
&#xD;
        1. meropenem-vaborbactam 4 g (meropenem 2 g- vaborbactam 2 g) therapeutic dose infused&#xD;
           intravenously over 3 hours&#xD;
&#xD;
        2. meropenem-vaborbactam supratherapeutic dose to be determined infused intravenously over&#xD;
           3 hours.&#xD;
&#xD;
        3. Placebo (normal saline) to match meropenem-vaborbactam volume infusion over 3 hours&#xD;
&#xD;
        4. Moxifloxacin 400 mg positive control (oral; open-label)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Thorough-QT (TQT) study in healthy volunteers will be conducted in two phases. Phase One&#xD;
      (n=15) will be used to identify a safe supratherapeutic dose to be used in the TQT study&#xD;
      (Phase Two). Phase Two will be a randomized, placebo and positive-controlled, 4-way crossover&#xD;
      TQT study. Thirty-two subjects will receive all 4 of the following treatments in randomized&#xD;
      sequence.&#xD;
&#xD;
        1. meropenem-vaborbactam 4 g (meropenem 2 g- vaborbactam 2 g) therapeutic dose infused&#xD;
           intravenously over 3 hours&#xD;
&#xD;
        2. meropenem-vaborbactam supratherapeutic dose to be determined infused intravenously over&#xD;
           3 hours.&#xD;
&#xD;
        3. Placebo (normal saline) to match meropenem-vaborbactam volume infusion over 3 hours&#xD;
&#xD;
        4. Moxifloxacin 400 mg positive control (oral; open-label)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Actual">November 19, 2018</completion_date>
  <primary_completion_date type="Actual">November 19, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Only Moxifloxacin will be administered open-label.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Placebo-corrected change-from-baseline QTcF interval (ΔΔQTcF)</measure>
    <time_frame>24 hours after start of dosing</time_frame>
    <description>Change in placebo corrected QTcF after dosing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change-from-baseline HR</measure>
    <time_frame>24 hours after start of dosing</time_frame>
    <description>Change in HR after dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change-from-baseline QTcF inteval</measure>
    <time_frame>24 hours after start of dosing</time_frame>
    <description>Change in QTcF after dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change-from-baseline PR interval</measure>
    <time_frame>24 hours after start of dosing</time_frame>
    <description>Change in PR after dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change-from-baseline QRS interval</measure>
    <time_frame>24 hours after start of dosing</time_frame>
    <description>Change in QRS after dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change-from-baseline RR interval</measure>
    <time_frame>24 hours after start of dosing</time_frame>
    <description>Change in RR after dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change-from-baseline QT interval</measure>
    <time_frame>24 hours after start of dosing</time_frame>
    <description>Change in QT interval after dosing</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with treatment emergent adverse events as assessed by CTCAE v4.3</measure>
    <time_frame>7 days after treatment</time_frame>
    <description>Safety evaluation (non-serious Treatment Emergent Adverse Events) of high dose of meropenem-vaborbactam</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with treatment emergent serious adverse events as assessed by CTCAE v4.3.</measure>
    <time_frame>7 days after treatment</time_frame>
    <description>Safety evaluation (serious Treatment Emergent Adverse Event) of high dose of meropenem-vaborbactam</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>meropenem 2 g- vaborbactam 2 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approved Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>meropenem-vaborbactam (dose TBD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Supratherapeutic Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin 400 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active Control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>meropenem-vaborbactam</intervention_name>
    <description>Meropenem-Vaborbactam being studied for effects on TQT</description>
    <arm_group_label>meropenem 2 g- vaborbactam 2 g</arm_group_label>
    <arm_group_label>meropenem-vaborbactam (dose TBD)</arm_group_label>
    <other_name>Vabomere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Normal Saline (placebo)</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Active Comparator</description>
    <arm_group_label>Moxifloxacin 400 mg</arm_group_label>
    <other_name>Moxi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subject between 18 and 55 years of age, inclusive, with a body mass&#xD;
             index (BMI) ≥18 to ≤33 kilogram (kg)/m2.&#xD;
&#xD;
          2. All women of child-bearing potential must agree to use an adequate method of&#xD;
             contraception during the study and for 30 days after the last dose. Accepted methods&#xD;
             of contraception include: mechanical products (e.g., intrauterine device) or&#xD;
             double-barrier methods (e.g., diaphragm, condoms, cervical cap) with spermicide or&#xD;
             hormonal contraceptives (i.e., oral, implanted or injectable contraceptive hormones)&#xD;
             or abstinence. Oral contraceptives must be used together with a second method of birth&#xD;
             control. If the female subject has a male partner who has had a vasectomy, one&#xD;
             additional form of medically acceptable contraception (condom or spermicide) must also&#xD;
             be used. The subject's understanding of this requirement must be documented by the&#xD;
             Investigator.&#xD;
&#xD;
             Males with female partners of childbearing potential must agree to use a highly&#xD;
             effective, medically acceptable form of contraception from the Screening period&#xD;
             through 30 days after the last dose. Males with female partners of childbearing&#xD;
             potential who themselves are surgically sterile (status post vasectomy) must agree to&#xD;
             use condoms with spermicide over the same period of time. Male subjects must agree to&#xD;
             practice the above birth control methods for 30 days after the final dose. Males must&#xD;
             agree to not donate sperm through 30 days after the final dose.&#xD;
&#xD;
          3. Stable health based on no clinically-significant findings on the medical history,&#xD;
             physical examination, or clinical laboratory test results at screening and prior to&#xD;
             study drug administration (as determined and documented by the Investigator).&#xD;
&#xD;
          4. Willing to comply with all study activities and procedures and provides written&#xD;
             informed consent prior to any study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known hypersensitivity to beta-lactam antibiotics (including meropenem),&#xD;
             fluoroquinolone antibiotics (including moxifloxacin) or vaborbactam.&#xD;
&#xD;
          2. An uninterpretable or abnormal screening electrocardiogram (ECG) indicating a second&#xD;
             or third degree atrioventricular block, or any rhythm other than sinus rhythm that is&#xD;
             interpreted by the investigator to be clinically significant or one or more of the&#xD;
             following: QRS interval &gt;110 milliseconds (ms); QTcF &gt;430 ms (males) and &gt;450 ms&#xD;
             (females); PR interval &gt;200 ms; heart rate (HR) &lt;50 beats per minutes (bpm); or &gt;90&#xD;
             bpm.&#xD;
&#xD;
          3. History of risk factors for torsades de pointes, including unexplained syncope, known&#xD;
             long QT syndrome, heart failure, myocardial infarction, angina. Subjects will also be&#xD;
             excluded if there is a family history of long QT syndrome or Brugada syndrome or&#xD;
             unexplained sudden death.&#xD;
&#xD;
          4. Subject has any clinically relevant abnormalities, as determined by the Investigator,&#xD;
             in the laboratory results at Screening or admission of each study period&#xD;
&#xD;
          5. Serum potassium, serum magnesium, or albumin-corrected calcium lower than the lower&#xD;
             limit of normal for the reference lab at Screening or admission of each study period.&#xD;
             Calcium will be corrected for albumin using the formula: Corrected Calcium = (0.8 *&#xD;
             (Normal Albumin - Pt's Albumin)) + Serum Ca where Normal Albumin is 4.0 g/dL.&#xD;
&#xD;
          6. Hemoglobin and hematocrit lower than the lower limit of normal for the reference lab&#xD;
             at Screening.&#xD;
&#xD;
          7. Subject has an abnormal liver function tests: alanine aminotransferase [ALT],&#xD;
             aspartate aminotransferase [AST], or bilirubin greater than 1.2X the upper limits of&#xD;
             normal at Screening.&#xD;
&#xD;
          8. History of central nervous system (CNS) disorder including convulsions.&#xD;
&#xD;
          9. A sustained supine systolic blood pressure &gt;140 mmHg or &lt;90 mmHg or a supine diastolic&#xD;
             blood pressure &gt;90 mmHg or &lt;50 mmHg at Screening or Check in (Day -1). Blood pressure&#xD;
             may be retested once in the supine position. The blood pressure abnormality is&#xD;
             considered sustained if either the systolic or the diastolic pressure values are&#xD;
             outside the stated limits after 2 assessments, in which case the subject should not be&#xD;
             randomized.&#xD;
&#xD;
         10. Impaired renal function as evidenced by estimated glomerular filtration rate (eGFR)&#xD;
             &lt;50.&#xD;
&#xD;
         11. Unstable cardiovascular disease, including recent myocardial infarction or cardiac&#xD;
             arrhythmia.&#xD;
&#xD;
         12. History of acquired immunodeficiency syndrome or history of a positive test result for&#xD;
             human immunodeficiency virus (HIV), hepatitis C virus (HCV) antibody, or hepatitis B&#xD;
             surface antigen (HBsAg) at Screening.&#xD;
&#xD;
         13. Positive drug, alcohol, or tobacco screen.&#xD;
&#xD;
         14. Clinically-significant illness, including viral syndromes within 3 weeks of dosing.&#xD;
&#xD;
         15. Women who are pregnant (or planning to become pregnant within the next 6 months) or&#xD;
             currently breastfeeding. A negative serum pregnancy test is required before enrolling&#xD;
             in the study.&#xD;
&#xD;
         16. Participation in another investigational drug or device study or treated with an&#xD;
             investigational drug within 30 days or 5 half lives, whichever is longer, before&#xD;
             dosing. Any subject who participated in Phase One of this trial is not eligible to&#xD;
             participate in Phase Two.&#xD;
&#xD;
         17. Consumed more than 28 units of ethanol per week at any time in the 6 months before&#xD;
             dosing (1 unit of ethanol is equivalent to 8 ounces of beer, 4 ounces of wine, or 1&#xD;
             ounce of spirits) or history of alcoholism and/or drug/chemical abuse.&#xD;
&#xD;
         18. Use of prescription medications (with the exception of oral contraceptives and hormone&#xD;
             replacement therapy), including nonsteroidal anti-inflammatory drugs or sucralfate and&#xD;
             medications known to prolong the QT/QTc interval or natural health products/herbal&#xD;
             preparations within 14 days or 5 half lives (whichever is longer) before study drug&#xD;
             dosing, or use of an over-the-counter (OTC) medication (excluding acetaminophen),&#xD;
             vitamins, or supplements (including omega-3 fish oils) within 7 days before study drug&#xD;
             dosing.&#xD;
&#xD;
         19. Use of alcohol , caffeine , or xanthine containing products, Seville oranges (sour),&#xD;
             grapefruit, or grapefruit juice, within 72 hours before study drug dosing.&#xD;
&#xD;
         20. Current use or has used tobacco- or nicotine-containing products (e.g., cigarettes,&#xD;
             cigars, chewing tobacco, snuff, etc.) 30 days before study drug dosing.&#xD;
&#xD;
         21. Strenuous activity (e.g., sports) from 96 hours (4 days) prior to entry into the&#xD;
             clinical research unit and throughout the study (until the final follow-up call is&#xD;
             conducted).&#xD;
&#xD;
         22. Donated more than 500 milliliter (mL) of blood or significant blood loss within 60&#xD;
             days prior to signing the informed consent form.&#xD;
&#xD;
         23. Any other medical, psychological, or social condition that, in the opinion of the&#xD;
             principal investigator or the medical monitor, would prevent the subject from fully&#xD;
             participating in the study, would represent a concern for study compliance, or would&#xD;
             constitute a safety concern to the subject.&#xD;
&#xD;
         24. An employee of the investigator or study center with direct involvement in the&#xD;
             proposed study or other studies under the direction of that investigator or study&#xD;
             center, as well as a family member of the employee or investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sue Cammarata</last_name>
    <role>Study Director</role>
    <affiliation>Melinta Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pharmaron Cpc, Inc</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>April 30, 2018</study_first_submitted>
  <study_first_submitted_qc>June 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2018</study_first_posted>
  <last_update_submitted>January 9, 2019</last_update_submitted>
  <last_update_submitted_qc>January 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Vaborbactam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

